LGVN News & Events

Reports Q1 revenue $398,000, consensus $323,000. "Earlier this year, we initiated a strategic repositioning of Longeveron designed to maximize shareholder value while maintaining disciplined capital allocation," said Stephen H. Willard, Chief Executive Officer of Longeveron. "We have transitioned toward a more capital-efficient, asset-light operating model, with an increased focus on securing strategic licensing partnerships for our stem cell therapy laromestrocel in four development programs. Longeveron is approaching a series of potentially transformative milestones across these programs that have the potential to redefine the trajectory of our business, with the first catalyst, top line results from our Phase 2b clinical trial in HLHS, anticipated in August of this year."

Longeveron announced that the independent data monitoring committee, or DMC, has completed its final prespecified data review for the ongoing, fully enrolled, Phase 2b clinical trial evaluating laromestrocel as a potential adjunct therapy for hypoplastic left heart syndrome. The DMC based its review on available data for all participating patients enrolled. The DMC performed a risk-benefit assessment, indicated no safety concerns, and approved the study to continue as designed to completion. ELPIS II enrolled 40 pediatric patients at 12 leading pediatric cardiac centers across the country.